针对端粒酶和瘤基因的新型阿克里衍生物 - 一种抗癌方法
Tiago J S Marques1, Diana Salvador2,3, Helena Oliveira2
1LAQV-REQUIMTE, Department of Chemistry, University of Aveiro 3810-193 Aveiro Portugal c.ramos@ua.pt.
RSC medicinal chemistry
|April 21, 2025
概括
两个新的阿克里衍生物,AcridPy和AcridPyMe,显示出作为G-四重复稳定剂和抗癌剂的前景. AcridPyMe通过稳定G-四重复DNA结构,特别是针对MYC瘤基因,显示出显著的抗癌活性.
科学领域:
- 药用化学 医学化学
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 在调节瘤基因方面,G-四重复的DNA结构至关重要.
- 目前正在探索阿克里衍生物的治疗潜力.
- 准G-四复合体为癌症治疗提供了一个新的策略.
研究的目的:
- 合成和评估新的阿克里衍生物,AcridPy和AcridPyMe,作为潜在的G-四重复稳定剂.
- 评估它们作为抗癌剂对各种瘤细胞系的有效性.
- 研究作用机制,包括DNA结合和细胞效应.
主要方法:
- 通过Heck合,电循环,氧化和N-甲基化合成AcridPy和AcridPyMe.
- 评估G-四重复DNA稳定性和选择性的生物物理方法.
- 分子动力学模拟用于预测结合相互作用 (例如,与MYC).
- 在胰腺,肺癌和黑色素瘤癌细胞系的体外细胞毒性测定.
- 在特定的癌症细胞系中进行细胞周期分析和细胞亡评估.
主要成果:
- 无论是AcridPy还是AcridPyMe都有效地稳定了G-四重复的DNA结构,对双重复的DNA具有选择性.
- 在AcridPyMe的研究中,MYC G-四重复结构具有优越的结合.
- 在体外,AcridPyMe对胰腺和黑色素瘤细胞系表现出显著的抗癌活性.
- AcridPyMe的抗癌作用与G-四重复稳定和诱导的亡有关.
结论:
- 新型的阿克里衍生物,AcridPy和AcridPyMe,是强大的G-四重复稳定剂.
- AcridPyMe显示出有前途的抗癌特性,使其成为潜在的治疗候选者.
- 针对G-四重复结构的新型阴离子烯是一种可行的策略,用于开发新的癌症疗法.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.6K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
10.9K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
02:38Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
02:15Replicative Cell Senescence
3.6K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
3.6K
02:41Telomeres and Telomerase
22.8K
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded...
22.8K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K